{"filing":{"accession_number":"0001477932-26-005526","cik":"0001464165","ticker":"BETRF","company_name":"BetterLife Pharma Inc.","form":"6-K","filing_date":"2026-09-11","report_date":"2026-09-11","primary_document":"betrf_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1464165/000147793226005526/betrf_6k.htm"},"events":[{"id":32785,"run_id":30140,"accession_number":"0001477932-26-005526","anchor_item_number":"EX-99.1","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"The exhibit discloses the appointment of Charles Duncan, PhD as Director and Chair of the Audit Committee in August 2026. While the filing also mentions stock option grants and warrant exercises, the principal disclosed action is the appointment of a director to a leadership governance role. Dr. Duncan's extensive biotechnology and capital markets background, combined with his appointment to chair the audit committee, represents a material governance event affecting board composition and oversight.","company_name":"BetterLife Pharma Inc.","ticker":"BETRF","filing_date":"2026-09-11","form":"6-K","submitted_at":null,"items":[{"id":36047,"accession_number":"0001477932-26-005526","item_number":"EX-99.1","item_title":"betrf_ex991.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The exhibit discloses the appointment of Charles Duncan, PhD as Director and Chair of the Audit Committee in August 2026. While the filing also mentions stock option grants and warrant exercises, the principal disclosed action is the appointment of a director to a leadership governance role. Dr. Duncan's extensive biotechnology and capital markets background, combined with his appointment to chair the audit committee, represents a material governance event affecting board composition and oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-11T10:06:26.694261+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36047,"accession_number":"0001477932-26-005526","item_number":"EX-99.1","item_title":"betrf_ex991.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The exhibit discloses the appointment of Charles Duncan, PhD as Director and Chair of the Audit Committee in August 2026. While the filing also mentions stock option grants and warrant exercises, the principal disclosed action is the appointment of a director to a leadership governance role. Dr. Duncan's extensive biotechnology and capital markets background, combined with his appointment to chair the audit committee, represents a material governance event affecting board composition and oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-11T10:06:26.694261+00:00","company_name":"BetterLife Pharma Inc.","ticker":"BETRF","filing_date":"2026-09-11"}]}